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Regular clinical follow up after breast cancer is a common practice. Evidence from retrospective reviews casts doubt on the efficacy of
this practice and the various guidelines for follow up show little concordance. Our aim was to investigate what alternative follow-up
methods (including reduced frequency of visits) have been subjected to controlled trial and to establish what evidence exists from
controlled trials to advise the guidelines. The study involved systematic review of the literature using MEDLINE, Embase, CancerLit,
Web of Sciences and EBM reviews as data sources. Methods included reviewing all randomised controlled trials comparing different
follow-up frequencies or comparing an alternative method with clinical follow up after breast cancer. All outcome measures
addressed in the trials were analysed. Two trials compared frequency of traditional follow up. Five trials assessed alternative methods.
All were of inadequate power or duration to establish ideal frequency of clinic visits or safety of alternative follow-up methods.
Alternative follow up had no detrimental effect on satisfaction or outcome. Few trials have been conducted, all of which are
underpowered to establish safety of reducing or replacing clinic visits. Alternative methods of follow up are acceptable to patients and
may be associated with other benefits. Larger trials are required.
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Regular follow up of patients after treatment for breast cancer is a
common practice. Aims of follow up include early detection of
treatable local recurrence, detection and treatment of side effects of
therapy and psychological support in the aftermath of diagnosis
and treatment (National Institute for Clinical Excellence, 2002).
Although it is generally felt that some form of follow up is
required, it is not clear what form it should take. Multiple
diagnostic interventions designed to detect metastatic disease are
now no longer recommended (National Institute for Clinical
Excellence, 2002; Grunfeld et al, 2005; Khatcheressian et al, 2006).
These do not prolong survival and are considered to have a
detrimental effect on the quality of life (Del Turco et al, 1994; The
GIVIO investigators, 1994; Palli et al, 1999). The only investigation
now conducted routinely is mammography, which has been shown
to detect contralateral disease at an earlier stage than clinical
examination alone (Mellink et al, 1991; Samant et al, 2001).
In addition to mammography, most clinicians recommend
routine clinic visits for history and clinical examination. However,
recommended frequency and duration of visits vary. The
American Society of Clinical Oncology recommends clinical
examination 3–6 monthly for 3 years, 6–12 monthly for a further
2 years and then annually (Khatcheressian et al, 2006). In contrast,
the National Institute for Clinical Excellence (NICE) in England
advocates follow up for only 2 or 3 years and gives no advice on
how frequently visits should be conducted (National Institute for
Clinical Excellence, 2002).
These marked variations in practice stem from a lack of
evidence that routine clinical examination is of benefit. The NICE
guidelines cite only one study, a retrospective review of 643
patients with median follow up of 3 years and 11 months, as
evidence for their recommendations for routine follow up
(Donnelly et al, 2001).
A recent systematic review designed to investigate long-term
outcomes in the setting of routine clinical follow up failed to
identify any trials comparing long-term results (survival/disease-
free survival) in patients with clinically detected local recurrence
vs symptomatic presentation of local recurrence (de Bock et al,
2004). The authors were unable to comment on whether routine
clinical examination during follow up conferred any survival
benefit (de Bock et al, 2004). However, they did report that routine
clinics following the American Society of Clinical Oncology
guidelines would detect only four asymptomatic recurrences in
every 100 women over 10 years of follow up, and would lead to
delayed diagnosis in two women who would notice problems
but wait for their next clinic appointment (de Bock et al, 2004).
A recent simulation model has also suggested that the
survival benefit of follow up would be at best marginal (Jacobs
et al, 2001).
It is clear that most retrospective reviews of routine clinic visits
have not been helpful in establishing either the best schedule for
such visits, or indeed whether such visits are necessary (de Bock
et al, 2004). However, the available evidence does appear to suggest
that the impact of routine follow up on survival will be at best
marginal and may lead to delayed diagnosis of recurrence.
The optimal design to study this issue would be a randomised
trial. Comparisons of different frequencies of visits to clinic or
different durations of follow up would be of particular value in
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sinforming guidelines. Comparisons of traditional follow up with
novel methods of care would help to establish whether traditional
clinic visits were necessary. It is the intention of this review to
identify any alternative methods of follow up, which has been
proposed and subjected to randomised trial. In addition, we intend
to establish whether there is any randomised, controlled evidence
to suggest an ideal length or schedule of follow up in order to
reconcile the various guidelines described above.
MATERIALS AND METHODS
We searched MEDLINE, Embase, EBM reviews, including the
Cochrane database, CancerLit and Web of Sciences for relevant
studies in May 2006. Any study published between 1966 and
present day was considered. The complete search string used is
reproduced as Appendix A. The complete search string used for
CancerLit is reproduced as Appendix B and for Web of Sciences as
Appendix C. This initial search was conducted independently by
authors DA Montgomery and K Krupa and titles were studied to
assess which abstracts should be obtained. All abstracts obtained
were read and considered independently by both DA Montgomery
and K Krupa to assess whether the full-length article should be
obtained. Sources of disagreement at this stage resulted in the full-
length article being obtained. References of all full-length articles
obtained were also searched for further relevant studies.
For all selected articles, MEDLINE, Embase, Web of Science and
CancerLit were searched for articles, which had subsequently been
published and had cited them.
Selection criteria
Studies were included if they fulfilled the following criteria:
1. Patients included had been treated for primary operable breast
cancer and were free of distant metastases outside the breast or
axilla at the time of initial treatment.
2. The study was a randomised controlled trial comparing routine
clinical and mammographic follow up with an alternative, or
comparing different frequencies or durations of clinical follow
up. Blinding of method of follow up to either clinicians or
patients was considered unnecessary.
Data extraction
Data were extracted by two investigators (DA Montgomery and
K Krupa) independently. Topics included number of patients,
percentage agreeing to randomisation, age, primary surgical
treatment, study comparison, follow up schedule and duration of
follow up.
Data were also extracted on the main outcome measures used
and how these were determined. Outcome measures included
patient satisfaction, quality of life, number of events (local
recurrence, distant recurrence, significant adverse events and
death) and economic analysis. Whether satisfaction and quality of
life were measured in a validated manner was also recorded.
Assessment of methodological quality
Methodological quality was also assessed independently by DA
Montgomery and K Krupa by means of a predefined form. This
form was derived from a number of sources, guided by a summary
by Greenhalgh (1997) on the measurement of methodological
quality in scientific trials and by the work of Altman and co-
workers (Altman and Lyman, 1998) and Laupacis et al (1994). The
results of this quality assessment are provided in Table 1.
RESULTS
In all, 2248 titles were examined in MEDLINE, 944 in EMBASE, 225
in EBM reviews, 2882 in CancerLit and 331 in Web of Sciences.
Five review, articles were also obtained in order to examine the
references for further relevant studies (Anonymous, 1998; Collins
et al, 2004; de Bock et al, 2004; Heys et al, 2005; Rojas et al, 2005).
In total, 20 abstracts were obtained.
From these abstracts, six full-length articles were obtained, all of
which were eligible for inclusion in the analysis (Grunfeld et al,
1996, 2006; Gulliford et al, 1997; Brown et al, 2002; Koinberg et al,
Table 1 Quality rating of included studies
Grunfeld
(1996)
Gulliford
et al (1997)
Brown et al
(2002)
Koinberg
et al (2004)
Baildam
et al (2004)
Kokko et al
(2005)
Grunfeld
et al (2006)
Is the population under study defined (with inclusion
and exclusion criteria)?
Yes Yes No
(exclusion
criteria
omitted)
Yes No Yes Yes
Are the main prognostic factors defined (at least age of
patient and stage of tumour)?
Yes Yes Yes Yes No Yes Yes
Is treatment of first tumour specified? Yes Yes Yes Yes No Yes Yes
Has a power calculation been carried out to assess the
required cohort size?
Yes No No Yes No No Yes
Is cohort size sufficient for primary outcome measure
(i.e. greater than any calculated sample size or of
sufficient size to detect clinically significant difference)?
Yes Yes No Yes Yes Yes No
Is a comparison made of baseline characteristics (age
and stage) between participants and those who refuse
to participate?
Yes Yes Yes No No No No
Is mean or median follow up greater than 5 years? No No No Yes Not given No No
Is loss during follow up specified? Yes No Yes No No No No
Is the follow up schedule (including mammographic
interval) specified?
Yes Yes No Yes No Yes Yes
Is mammographic frequency identical between
follow-up groups?
Yes Yes Yes Yes Not given Yes Yes
Are mostly objective or validated outcomes used? Yes No Yes Yes Yes Yes Yes
Were outcomes prospectively assessed? Yes Yes Yes Yes Yes Yes Yes
Was the article published in peer reviewed journal? Yes Yes Yes Yes No Yes Yes
Total score 12 9 8 11 3 9 9
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of the proceedings of a scientific meeting and the data had not yet
been published in full (Baildam et al, 2004). This abstract was also
included. In total, we identified seven randomised controlled trials
in the literature, all of which were eligible for inclusion.
Study characteristics
The characteristics of all seven included trials are provided in
Table 2.
Two trials compared follow up in hospital clinics with that
provided by a general practitioner (Grunfeld et al, 1996, 2006), two
compared traditional follow up with follow up merely on demand
by contacting a breast care nurse (Brown et al, 2002; Koinberg
et al, 2004) and one compared routine follow up by doctors with
routine follow up by breast care nurses (Baildam et al, 2004).
Two trials compared different frequencies of follow up within a
traditional framework (Gulliford et al, 1997; Kokko et al, 2005).
Methodological quality
As stated above, methodological quality was assessed by means of
a predefined form. Methodological quality in general among these
trials was good. However, one study (Baildam et al, 2004) scored
poorly on this form as a result of being presented only in abstract
form in the literature as part of the proceedings of an international
meeting. The average score was 8.7 out of 13, or 10.7 if Baildam
and co-workers are excluded.
Rating of methodological quality took into account intended
outcome measures when assessing adequacy of sample size and
follow-up duration. However, many of the trials had either
inadequate numbers of patients or insufficient follow-up duration,
or indeed both of these problems, for an analysis of long-term
survival to be conducted.
Detection of recurrence
Whether traditional clinical follow up is carried out 3 or 6 monthly
makes no difference to the overall number of recurrences detected
(Kokko et al, 2005). In 239 women followed up 3 monthly, there
were 66 recurrences, compared with 57 recurrences among 233
women followed up 6 monthly. Local recurrence was not dealt with
separately, however, and time to detection of recurrence was not
analysed. It is unclear whether further increasing follow up interval
to annual would have an effect on detection of local recurrence.
One study attempted to address this issue, but recruited only 196
patients and analysed after a median of 16 months follow up, so
had insufficient patient numbers and follow-up duration to
conduct such analysis (Gulliford et al, 1997).
There was no difference in the number of recurrences between
patients followed up by a physician and by a breast care nurse
(seven vs six, respectively, from 525 patients followed up for an
undisclosed time period) (Baildam et al, 2004). Time to recurrence
was again not presented.
More local recurrences were detected by nurses during on-
demand follow up than during routine visits in one trial (Koinberg
et al, 2004). Nurses detected 12 recurrences from 133 patients
compared with eight local recurrences detected by physicians from
131 patients. Again, these numbers are too small for this to be
significant, and there was no difference in the number of patients
diagnosed with metastatic disease. There were no significant
differences between the groups in terms of time to event for any of
the event types (time to locoregional recurrence, metastases or
death) analysed (data not shown).
In the first of the trials dealing with hospital follow up compared
with follow up in general practice, 296 patients were recruited,
148 in each type of follow up. There were similar numbers of
locoregional recurrences in each group, with four in the general
practice group and three in the hospital group. There were more
than twice as many metastatic recurrences diagnosed in the
hospital group (13 vs 6 in general practice, difference 4.7%, 95%
confidence interval (CI)  0.8 to 10.3%) (Grunfeld et al, 1996). Of
interest, while all the recurrences in the general practice group
were detected by the general practitioner, 44% of the recurrences
in the hospital follow up group were also diagnosed by the general
practitioner initially (Grunfeld et al, 1996).
In the second of the hospital vs general practice follow up trials,
there was again no significant difference in the proportion of
women presenting with local or distant recurrences between the
two groups (11.2% in general practice group compared with
13.2% in the hospital group, difference of 2.02%, 95% CI  2.13 to
6.16%). Time to recurrence detection is not provided (Grunfeld
et al, 2006).
Adverse clinical events
One trial addressed the issue of recurrence-related serious clinical
events (SCEs) (Grunfeld et al, 2006). The authors postulate that
early diagnosis of recurrence is likely to result in reduced rate
of serious events related to recurrence, such as spinal cord
compression from spinal metastases etc. They found no difference
in rate of SCEs between hospital and general practice follow up
(3.7% of patients vs 3.5%, respectively, difference 0.19%, 95% CI
 2.26 to 2.65%).
Survival
There was no difference between physician follow up or follow up
on demand by a breast care nurse in number of deaths, with 14
deaths from 131 physician followed up patients compared with 14
deaths from 133 patients followed up by a nurse. Overall survival
on Kaplan–Meier curves was similar for the two groups also (data
not shown) (Koinberg et al, 2004).
One study showed a slight excess in mortality in hospital follow
up compared with general practice (Grunfeld et al, 1996). The
difference was not further analysed as the numbers were small,
with only two deaths in the general practice group and seven in the
hospital group from 148 patients in each cohort. Moreover, this
difference did not exist over longer follow up in a much larger
cohort of 968 women in a subsequent trial of hospital follow up
compared with general practice by the same authors (Grunfeld
et al, 2006). In this latter trial, there were 29 deaths in the general
practice group and 30 in the hospital group.
Satisfaction
Willingness to participate (percentage randomisation) is provided
in Table 2.
Two studies looked at satisfaction with an alternative method of
follow up. One used a structured interview technique (Brown et al,
2002), whereas the other employed a questionnaire previously
validated by the authors (Koinberg et al, 2004). Both reported high
levels of satisfaction with follow up in both study and control
groups, with no difference in satisfaction between the study and
control groups in either trial. In the patient-initiated follow-up
trial by Brown et al, there were differences in what patients
perceived as advantages of different methods of follow up, with
more women describing routine clinic visits as reassuring
(w
2:27.63, Po0.000, 1 df), whereas more men described on-
demand follow up as convenient (w
2:17.354, Po0.000, 1 df) (Brown
et al, 2002).
Within a traditional follow-up schedule, frequency can be
reduced with no loss of satisfaction (Gulliford et al, 1997).
Moreover, similar numbers in the high- and low-frequency groups
will express a desire for lower- or higher-frequency visits than they
received during the trial (Gulliford et al, 1997).
Alternative breast cancer follow-up methods
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sTable 2 Characteristics of included studies
Study Year Patient group
Percentage
randomisation Age
Primary
therapy Study design
Main outcome
measures Follow-up schedule
Duration of
study or
median
follow up
Grunfeld 1996 Two hundred and
ninety-six primary
operable patients
attending routine
follow up at all stages
of follow up and free
of metastatic disease
66.5% Mean 59.1 GP
and 62.4
hospital (s.d.
10.3 and 12)
53%
mastectomy,
47% Breast
Conservation
(BCT)
Randomised
controlled trial
of follow up in
general practice
vs hospital.
Quality of life as
measured by several
validated questionnaires.
Number of recurrences.
Number of deaths.
Time to diagnose
recurrence from onset
of symptoms.
No data on survival
3 monthly clinical
examination and history
during the first year, 6
monthly for 4 years, then
annual in one hospital,
with 3 monthly first year,
4 monthly second year, 6
monthly for 5 years and
then annual in the other.
General practice group
as per hospital of
diagnosis. One to two
yearly mammograms.
18 months
Gulliford 1997 One hundred and
ninety-six primary
operable patients
attending routine
follow up over a
24-month period at all
stages of follow up and
free of metastatic
disease
93% 56 o49 years,
96 ¼50–65
years and 41
465 years
68% BCT, 32%
mastectomy
Comparison of
frequent follow
up vs annual
follow up
Acceptability of
randomisation and
overall satisfaction.
Interim use of
telephone and
general practioner.
No data on survival
or quality of life
3 monthly clinical
examination and
history during first
year, 4 monthly second
year, 6 monthly for 5
years and then annual.
One to two yearly
mammogram, depending
on whether mastectomy
or BCT in the control
group, annual clinical
examination, history and
mammogram in the trial
group
Median 16
months
Brown 2002 Sixty-one primary
operable patients
attending routine
follow up at all stages
of follow up and free
of metastatic disease
50% Mean 63
standard clinic,
68 in patient
initiated
66% BCT,
34%
mastectomy
Traditional clinic
follow up vs
patient-initiated
follow up
Quality of life using
validated questionnaires
and satisfaction using
unvalidated structured
interview.
NO data on survival
4–6 monthly clinical
examination and history
for first 5 years then
annual in control
group vs on request
only in the study
group. Annual
mammograms in both
12 months
Koinberg 2004 Two hundred and
sixty-four primary
operable patients
attending routine
follow up at all stages
of follow up and free
from metastatic
disease
Not given 58.8 (s.d. 10.1)
in traditional
group, 60
(s.d. 10.3) in
the on demand
group
84% BCT, 16%
mastectomy
Traditional clinic
follow up vs
follow up on
demand
coordinated by
a breast care
nurse
Quality of life and
satisfaction using
validated questionnaires.
Number of contacts with
health professionals.
Number of events and
survival
3 monthly clinical
examination and
history for 2 years,
6 monthly for 3 years
then annual for 5 years
and annual mammogram
in traditional follow-up
group, with
appointments on
demand only and annual
mammograms in the
nurse-led follow up on
demand group
5 years
Baildam 2004 Five hundred and
twenty-five primary
operable patients
attending routine
follow up at all stages
of follow up and free
of metastatic disease
78% Not given Not given Comparison
of standard
follow up
with those
by hospital
doctors or
specially
trained breast
care nurses
Number of events
Anxiety by validated
questionnaire.
Satisfaction using
validated questionnaire.
Economic comparison
NO survival comparison
Not given, but
identical for both
arms
Not given
Kokko 2005 Four hundred and
seventy-two primary
operable patients
attending routine
follow up at all stages
of follow up and free
of metastatic disease
Not given 56.9 in
frequent
follow up
group, 60 in
infrequent
group
54%
mastectomy,
46% BCT
A comparison
of 3 vs 6
monthly follow
up (and of
intense vs as
required
investigations)
Event detection and
cost per event
detected
No data on survival
3 vs 6 monthly
clinical examination
and history.
Median 4.2
years
Grunfeld 2006 Nine hundred and
sixty-eight women
between 9 and 15
months after diagnosis
of early-stage breast
cancer, who had
completed treatment
and were disease free
55% Mean 60.9
(in both
groups)
73% BCT, 20%
mastectomy
and 7% biopsy
only
A comparison
of follow up
by general
practioner vs
hospital
follow up
Quality of life using
validated questionnaires.
Significant clinical
events (metastases
related).
Number of local
recurrences and deaths
3–6 monthly for
3 years, 6 monthly
for 2 years then
annual, with annual
mammogram
Median 4.5
years from
diagnosis
(3.5 from
randomisation)
Abbreviations: BCT¼breast conservation; s.d.¼standard deviation.
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sIn the trial by Baildam et al (2004), the Fallowfield Satisfaction
with Consultation Questionnaire revealed that women were
significantly more satisfied with their consultation with a nurse
than those seen by a doctor (Po0.001).
Quality of life
Several trials looked at the issue of quality of life measured by
validated tools such as the hospital anxiety and depression scale
(HADS) (Grunfeld et al, 1996, 2006; Brown et al, 2002; Baildam
et al, 2004; Koinberg et al, 2004), European Organisation for
Research and Treatment of Cancer (EORTC) QLQ-C30 and BR23
(Grunfeld et al, 1996; Brown et al, 2002) and the Medical Outcomes
Study Short Form 36-item General Health Survey (SF-36)
(Grunfeld et al, 1996, 2006). None of these trials reported any
differences in any of the scales between control and study groups
at any stage in the respective trials.
Although there were no differences in quality of life between
control and study groups in any of the trials, one group did report
that nurses were better at recognising psychological distress than
doctors (Baildam et al, 2004). From a cohort of 525 women, 86
patients had a psychological distress indicated by HADS scores,
49 seen by a nurse and 37 by a doctor. Whereas nurses failed to
recognise this in 47%, doctors missed distress in 92% of these
women.
Economic analyses and workload concerns
Unsurprisingly, reducing the frequency of clinic follow up is
shown to reduce the cost of follow up, with a mean cost of follow
up of 1656h in the 3 monthly follow up group compared with
1050h per patient in the 6 monthly follow up group over 4.2 years
of follow up (Kokko et al, 2005). There was no increase in the
number of phone calls or visits to general practitioners as a result
of reduced frequency of follow up visits (Gulliford et al, 1997).
Another study revealed no advantage of breast care nurse follow
up over follow up by clinicians in terms of cost (data not shown)
(Baildam et al, 2004). This finding was attributed to the fact that
nurses spent longer with individuals than doctors, and that very
senior nursing staff were required.
Grunfeld et al (1996) subsequently published the results of an
economic analysis of follow up in hospital compared with follow
up by General practitioner (Grunfeld et al, 1999). General practice
patients were seen significantly more frequently and each visit was
significantly longer during the 18 months of the trial than were
hospital patients. In addition, while overall numbers of tests were
similar, general practitioners requested significantly more blood
tests, mammograms and chest X-rays than specialists. Overall,
however, the cost to the health service was lower for general
practice follow up than for follow up in hospital (Grunfeld et al,
1999).
Follow up on demand by breast care nurses results in
significantly fewer clinical contacts. There were 450 fewer visits
to the physician and only 177 more phone calls, and 88 more visits
to the nurse in one study, so that there were 21% more primary
contacts in the physician group (Koinberg et al, 2004). There were
more mammograms in the nurse-led on-demand group, however.
DISCUSSION
Numerous guidelines exist for the follow up of breast cancer, with
little concordance between them. In the UK, The National Institute
for Clinical Excellence (NICE) recommends 2–3 years of follow up
then discharge to general practice (National Institute for Clinical
Excellence, 2002). The British Association of Surgical Oncology
(BASO) suggests discharge at 5 years (The Association of Breast
Surgery @ BASO and Royal College of Surgeons of England, 2005).
In sharp contrast, the American Society of Clinical Oncology
recommends 3–6 monthly visits for 5 years, followed by annual
visits indefinitely (Khatcheressian et al, 2006), and the Canadian
Steering Committee similarly advocates indefinite follow-up visits
for clinical examination (Grunfeld et al, 2005). But which of these
organisations is correct?
Routine clinical examination after treatment for breast cancer is
an inefficient way of detecting recurrent disease (de Bock et al,
2004). Intuitively, more frequent clinic visits should lead to earlier
detection of recurrence and improved survival at the cost of
reduced efficiency. However, there is no evidence in the literature
that this is the case.
Only two randomised controlled trials have attempted to
address the frequency of follow up (Gulliford et al, 1997; Kokko
et al, 2005). Neither provided clear answers. Kokko et al (2005)
demonstrated that 3 and 6 monthly follow ups are equivalent in
terms of event detection, but made no comment on survival and
did not separate locoregional from distant recurrence. The trial by
Gulliford et al (1997)was insufficiently powered to comment on the
safety of reducing follow up to annual visits. No randomised trials
have looked at the issue of when patients should be discharged
from clinic.
Five randomised controlled trials exist comparing traditional
follow up with some alternative (Grunfeld et al, 1996, 2006; Brown
et al, 2002; Baildam et al, 2004; Koinberg et al, 2004). However,
the authors have largely sought to measure outcomes such as
acceptability to patients, satisfaction, quality of life etc. Most of the
trials have resultantly been underpowered or of inadequate
duration to address the issue of survival.
Those investigators who have attempted to address the issue
of survival have shown no disadvantage to follow up without the
hospital setting, either by general practitioner (Grunfeld et al,
2006) or on demand by a specialist nurse (Koinberg et al, 2004). In
one of these trials, almost 1000 women were followed until 4 and a
half years after treatment and survival, locoregional and distant
recurrence detection and incidence of recurrence-related SCEs
were identical in both arms (Grunfeld et al, 2006). However, event
rates will be small even in such a large cohort of women. In 1312
women in Edinburgh followed for a median duration of 10 years,
only 110 treatable locoregional recurrences occurred, with only 15
diagnosed by clinical examination, the rest being either sympto-
matic or mammographically detected (personal communication).
Therefore, despite the large recruitment and reasonable duration
of follow up in the trial by Grunfeld and co-workers, even this trial
was insufficiently powered to show a difference in outcome related
to follow up.
Two trials have demonstrated a trend to more locoregional
recurrences being detected by alternative follow up methods
(Grunfeld et al, 1996; Koinberg et al, 2004). Both trials were of a
limited duration. With longer follow up, the question of whether
this represents earlier detection of locoregional recurrence during
non-hospital based follow up, and whether this would result in
improved long-term survival with these alternative methods of
follow up, may have been answered. Certainly, large meta-analyses
have reported that routine clinical follow up results in delayed
diagnosis of locoregional recurrence in two-thirds of women who
develop recurrence (de Bock et al, 2004).
None of the trials revealed any reduction in the quality of life or
increase in levels of stress associated with alternative follow up
(Grunfeld et al, 1996, 2006; Brown et al, 2002; Baildam et al, 2004;
Koinberg et al, 2004). Moreover, alternative follow up methods
appear to be acceptable to women, as evidenced by high
randomisation rates. The alternative methods can be more cost
effective and reduce workload at busy specialist clinics (Gulliford
et al, 1997; Grunfeld et al, 1999). So why have so few investigators
made any serious attempt to address this issue?
In correspondence published in response to the original trial by
Grunfeld et al (1996), there was support from general practitioners
Alternative breast cancer follow-up methods
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from breast surgeons that clinical examination was central to the
detection of locoregional recurrence, and that those conducting
such examination should have some degree of specialisation
(Dixon and Norman, 1996; Rainsbury, 1996). They warn that non-
specialists may be less able to detect locoregional recurrence,
especially in those who have had breast conserving therapy, or
to detect metastatic disease when it presents with nonspecific
symptoms (Rainsbury, 1996).
Rodger asserts that clinicians gain the experience they have in
detecting recurrent disease by frequent examination of a range of
normal. Reducing clinical follow up may result in de-skilling of
clinicians, or at least reduced experience of those currently in
training (Rodger, 1997). In addition, removing patients from
routine follow up would have the effect that clinicians only see
patients with problems. This may lead to reduced job satisfaction
and the risk of subsequent burnout (Khatcheressian and Smith,
2006). While these are valid concerns, it does raise the question of
whether we follow up well patients for their benefit or ours.
Whatever clinicians perceive as their reasons for continuing
with clinical follow up, it is the perception we have of patients’
expectations that has done the most in reducing our exploration of
alternative follow up methods. While the idea of coming back to
specialist clinics less frequently is associated with a high degree of
acceptance among women, as evidenced by a 93% randomisation
to annual follow up in the trial by Gulliford et al (1997), the idea of
non-specialist follow up is less acceptable. Randomisation rates for
the two trials involving follow up by a non-specialist were 55 and
66.5% (Grunfeld et al, 1996, 2006). Morris et al (1992) reported
that 81% of women in routine breast cancer follow up were
reassured by the clinic and 76% preferred hospital clinics to being
followed up in general practice. Similar findings have been
reported by others (Kiebert et al, 1993; Paradiso et al, 1995;
Renton et al, 2002).
When surveyed about their perceptions of cancer follow up,
patients have expressed anger and distress about being discharged
to their general practitioner (Maher et al, 1995). Patients viewed
the hospital, and in particular diagnostic tests, specialist physi-
cians and breast care nurses, as their best defence against
recurrence. While they do report that there are negative points
to coming to clinic – rushed consultations, long waiting times and
lack of continuity of care – these are seen as an acceptable trade off
for guarding against a relapse (Maher et al, 1995).
However, many women find follow up visits stressful. In one
survey, almost half of the patients reported to be worried, anxious
or frightened before appointments (Renton et al, 2002), and
psychological stress is significantly higher among cancer patients a
month before and on the day of clinic visits than 2 weeks after
that (Kiebert et al, 1993). Up to 70% of breast cancer patients
may suffer distress during routine clinical follow up (Paradiso
et al, 1995).
None of the trials of alternative methods of follow up included
here set out to measure the psychological stress of attending clinic.
As a result, it is not clear whether alternative methods of follow up
have less attendant stress. Replacing routine clinical follow up with
some alternative does not appear to have a negative impact on
patient psychological well being in general. In the studies, which
reported on quality of life, there was no reduction in scores among
patients in the trial group either compared with baseline or
compared with the control patients (Grunfeld et al, 1996, 2006;
Brown et al, 2002; Baildam et al, 2004; Koinberg et al, 2004).
However, there was no improvement in the quality of life scores
either.
SUMMARY
The current recommendations for follow up are inconsistent
(National Institute for Clinical Excellence, 2002; Grunfeld et al,
2005; Khatcheressian et al, 2006). This systematic review of the
literature highlights the underlying reasons for the limitations in
the recommendations.
There are no randomised trials in the literature with sufficient
power to recommend an acceptable frequency or duration of
follow up. Moreover, there are no randomised trials, which can
confirm the safety of using alternative follow-up methods. Those
studies, which have been conducted have not suggested that
alternative methods are any less safe than routine clinical follow up
(Grunfeld et al, 1996, 2006; Koinberg et al, 2004), but recruitment
and duration are such that the only conclusion, which can be
made is that the necessity for clinical examination and the safety of
alternative follow up has not been proven.
Traditional routine clinic visits are an inefficient way of
safeguarding against recurrent disease, and there is doubt as to
whether they provide the ideal setting for providing psychological
support to patients. Alternative follow-up methods are acceptable
to patients, are associated with no reduction in the quality of life or
increase in anxiety and may be conducted with significant
economic and time savings.
More high-quality, randomised controlled trials in this area are
required in order to establish how best to provide effective
psychosocial support to patients after treatment of breast cancer,
while at the same time maintaining adequate surveillance to detect
those few treatable relapses which occur.
Clinicians involved in the care of breast cancer patients need to
be clear about what their objectives are regarding follow up after
breast cancer, both in their own minds and to their patients. Only
then can we design and evaluate efficient follow-up programmes to
meet those objectives, while at the same time providing patients
with a realistic view of what we are trying to achieve.
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Appendix A
Search string used to identify relevant studies
Appendix B
Search string used to identify relevant studies in CancerLit
1 Adult/
2 ‘Aged 80 and over’/or aged/ or middle aged/
3 (neoplasm$ or cancer$ or tumour$ or tumour$ or malign$ or carcinoma$
or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$ or
intraduct$ or lobular$ or medullary$).mp.
4 breast.mp.
5 3 and 4
6 (follow up or follow-up or recurrence).mp. [mp¼ti, ab, tx, kw, ct, ot,
sh, hw]
7 1 and 2 and 5 and 6
8 Quality of life.mp. or ‘Quality of Life’/
9 patient satisfaction.mp. or Patient Satisfaction/
10 survival rate.mp. or Survival Rate/
11 8 or 9 or 10
12 7 and 11
1 Adult/
2 ‘Aged, 80 and over’/ or Aged/ or Middle Aged/
3 (neoplasm$ or cancer$ or tumour$ or tumor$ or malign$ or carcinoma$
or adenocarcinoma$ or sarcoma$ or dcis or ductal or infiltrat$ or
intraduct$ or lobular$ or medullary$).mp.
4 breast.mp.
5 3 and 4
6 (follow up or follow-up or recurrence).mp. [mp¼ti, ab, tx, kw, ct, ot, sh, hw]
7 1 and 2 and 5 and 6
8 Quality of life.mp. or ‘Quality of Life’/
9 patient satisfaction.mp. or Patient Satisfaction/
10 survival rate.mp. or Survival Rate/
11 8 or 9 or 10
12 7 and 11
13 11 and randomised
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Search string used to identify relevant studies in Web of Sciences
1T S ¼(neoplasm* or cancer* or tumour* or tumor* or malign* or
carcinoma* or adenocarcinoma* or sarcoma* or dcis or ductal or infiltrat*
or intraduct* or lobular* or medullary*)
2T S ¼breast
3 1 and 2
4T S ¼(follow up or follow-up or recurrence)
5 1 and 2 and 4
6 1 and 2 and 4 and randomised
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